Drug Type Small molecule drug |
Synonyms Imaradenant, AZD 4635, HLT 1071 + [1] |
Target |
Action antagonists |
Mechanism A2aR antagonists(Adenosine A2a receptor antagonists) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC15H11ClFN5 |
InChIKeyNCWQLHHDGDXIJN-UHFFFAOYSA-N |
CAS Registry1321514-06-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic castration-resistant prostate cancer | Phase 2 | United States | 29 Aug 2019 | |
metastatic non-small cell lung cancer | Phase 2 | United States | 08 May 2018 | |
metastatic non-small cell lung cancer | Phase 2 | South Korea | 08 May 2018 | |
Non-Small Cell Lung Cancer | Phase 2 | United States | 08 May 2018 | |
Non-Small Cell Lung Cancer | Phase 2 | China | 08 May 2018 | |
Non-Small Cell Lung Cancer | Phase 2 | South Korea | 08 May 2018 | |
Advanced Malignant Solid Neoplasm | Phase 1 | United States | 17 Jun 2016 | |
Castration-Resistant Prostatic Cancer | Phase 1 | United States | 17 Jun 2016 | |
Metastatic Colorectal Carcinoma | Phase 1 | United States | 17 Jun 2016 | |
Metastatic Prostate Carcinoma | Phase 1 | United States | 17 Jun 2016 |
Phase 1 | Advanced Malignant Solid Neoplasm adenosine A2A receptor | 10 | Imaradenant 50 mg QD | bfhknspfsc(gdumojspqw) = The most common adverse events were nausea, malaise, decreased appetite, and vomiting. jgesjerssw (fpfxytvjep ) View more | Positive | 01 Apr 2024 | |
NCT04089553 (Pubmed) Manual | Phase 2 | 59 | xuygifgbuu(pfweklxise) = vncmcthwvc jmyuvuniul (jblafesoty ) View more | Negative | 02 Mar 2024 | ||
rtjnofuint(qbowncscaq) = sixzgqvzyi rvtuzwphrw (czjjhzbhuw ) View more | |||||||
Phase 2 | 30 | (Arm A: AZD4635 + Durvalumab) | naqdptdfsb(gyehyizzjh) = leknknnrzi bedvytuqba (uoqoifzrnf, egodgdhhgq - wmpptubfxa) View more | - | 09 Aug 2023 | ||
(Arm B: AZD4635 + Durvalumab + Cabazitaxel) | nojzvphbti(vefqoybvyv) = ajinliovhk kbuomrcjoy (gpimmvftsk, zpvpqtbhdw - vptkrcexet) View more | ||||||
Phase 2 | 28 | zpsgwyuarl(ntvjoqhdgf) = puzqzydiou qsuebglpyu (hgwdcxgnku, 4.2–NE) View more | Negative | 21 Feb 2023 | |||
NCT04089553 (ESMO2022) Manual | Phase 2 | 59 | AZD4635 75 mg+Durvalumab 1500 mg | lisxplujzm(vzinwlqeuo) = tmdnedmzeh kbgctdqaqq (jbxfjslvbt ) View more | Negative | 10 Sep 2022 | |
AZD4635 50 mg or 75 mg+Oleclumab 1500 mg | lisxplujzm(vzinwlqeuo) = sjcyduumwx kbgctdqaqq (jbxfjslvbt ) View more | ||||||
Phase 2 | 59 | (Module 1 (AZD4635 75 mg + Durvalumab 1500 mg)) | aiwaqffoxx = yfeqrnnvvk kjdqojhixp (vjktruhthk, qpbxuwxmyb - nevuntlwvy) View more | - | 08 Jul 2022 | ||
aiwaqffoxx = keqoxqubea kjdqojhixp (vjktruhthk, mdfvdgibnj - xbghboaiwn) View more | |||||||
Phase 1 | - | zyvwcaykzt(tdnqknclii) = yswtxobjhb ogpmxpwvqt (umrspsvcns ) View more | - | 15 Aug 2020 | |||
zzolrrhhei(supzcycrsw) = pwvwrdmjzu fhwxnppcuw (twbczeozex ) View more | |||||||
Phase 1 | 94 | xzrkktfmbb(ibofrzclgg) = nausea, vomiting, fatigue, decreased appetite, dizziness, and diarrhea. pwmvflqfrk (awpxtjtylp ) View more | Positive | 29 May 2020 | |||